Please login to the form below

Not currently logged in
Email:
Password:

EMA geriatric expert group

The European Medicines Agency has established an expert group to provide advice on issues related to the elderly as part of the agency's Committee for Medicinal Products for Human Use

The European Medicines Agency (EMA) has established an expert group to provide advice on issues related to the elderly as part of the agency's Committee for Medicinal Products for Human Use (CHMP).

The geriatric group consists of nine experts in the field who will assist the CHMP in several ways, including giving input on guidelines under consultation and adding a geriatric viewpoint on discussions concerning the development, assessment or safety monitoring of medicines.

Members will meet on an ad-hoc basis, communicating by e-mail, telephone conference or web conference rather than in person.

The creation of the group is part of the EMA's geriatric medicines strategy (PDF), published in February 2011.

The strategy was developed to take into account the changing environment of modern healthcare, with an increasingly ageing population.

The implementation of the strategy was described in the EMA's 'road map' to 2015, which identifies three priority areas for the agency to focus on: addressing needs in public health; facilitating access to medicines; and making sure use of medicines is safe.

8th June 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics